Cargando…
Hurdles to the Development of Effective HBV Immunotherapies and HCV Vaccines
Chronic infections with HBV and HCV continue to be major public health problems, with hundreds of millions of people infected worldwide; this is despite the availability of both an effective prophylactic HBV vaccine for more than 3 decades and potent direct antivirals for HBV and, more recently, HCV...
Autores principales: | Torres-Cornejo, Almudena, Lauer, Georg M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Pathogens and Immunity
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486412/ https://www.ncbi.nlm.nih.gov/pubmed/28664194 http://dx.doi.org/10.20411/pai.v2i1.201 |
Ejemplares similares
-
Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV
por: Tseng, Chih-Wei, et al.
Publicado: (2022) -
Therapeutic vaccines in HBV: lessons from HCV
por: Barnes, Eleanor
Publicado: (2015) -
Defining the critical hurdles in cancer immunotherapy
por: Fox, Bernard A, et al.
Publicado: (2011) -
Immunotherapy for Alzheimer’s disease: hoops and hurdles
por: Lemere, Cynthia A
Publicado: (2013) -
HBV and HCV Therapy
por: Lampertico, Pietro, et al.
Publicado: (2009)